doi.org/10.1016/s0140-6736(21)02188-7

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

..., Robert J. Heine
97
The Lancet88.50
Volume: 398, Issue: 10313, Pages: 1811 - 1824
Published: Oct 19, 2021
Paper Fields
Paper Details
Title
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
DOI
doi.org/10.1016/s0140-6736(21)02188-7
Published Date
Oct 19, 2021
Journal
The Lancet
Volume
398
Issue
10313
Pages
1811 - 1824
© 2026 Pluto Labs All rights reserved.